SPRING: A New Trial to Evaluate Tipranavir in Heterogeneous Treatment-Experienced HIV Populations
SPRING: A New Trial to Evaluate Tipranavir in Heterogeneous Treatment-Experienced HIV Populations
Eugenia Vispo
NULL
*Correspondence: Eugenia Vispo, Email not available
Abstract
There is an urgent need for safe, simple, and moreeffective regimens for the treatment of antiretroviralexperiencedHIV-positive patients, especially women,Blacks, Hispanics and Asians. To address thisneed, Boehringer-Ingelheim has initiated a trial,named SPRING (Safety, efficacy and Pharmacokineticsof tipRanavir boosted with low dose ritonavir(500/200 mg) twice daily IN 400 racially and Genderdiverse, antiretroviral-experienced HIV patients).
